With 3 quick buyouts, Gilead leans into its latest transformation
BioPharma Dive
On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it s long struggled to execute.
pharminent
April 8, 2026 (Last updated: April 9, 2026)
BioPharma Dive
On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it s long struggled to execute.
